The race bibs we wore always said, “I walk for Wilma Parnell,” my maternal grandmother, who died from breast cancer when my ...

The antibody-drug conjugate will be reviewed for the potential treatment of previously treated, unresectable or metastatic ...

The FDA grants priority review to AZN's sBLA for Enhertu to treat HER2-low or HER2-ultralow metastatic breast cancer. A ...

AstraZeneca and Daiichi Sankyo's supplemental Biologics License Application (sBLA) for Enhertu (trastuzumab deruxtecan) has ...

AstraZeneca and Daiichi Sankyo announced that their drug Enhertu (trastuzumab deruxtecan) has been granted Priority Review by the US FDA for trea ...

AstraZeneca (AZN) and Daiichi Sanyko (DSKYF)(DSNKY) said the FDA has accepted their application with priority review for ...

With this year's Breast Cancer Awareness Month now underway, we are sharing eight facts and updates about breast cancer that ...

Patients with HER2-positive metastatic breast cancer may consider related side effects and quality of life outcomes when choosing treatments.

The sBLA is supported by results from the phase IIIDESTINY-Breast06 trial (NCT04494425), which showed that patients with HER2 ...

Trastuzumab deruxtecan is a HER2-directed antibody and topoisomerase inhibitor conjugate currently marketed under the brand name Enhertu (fam-trastuzumab deruxtecan-nxki) for the treatment of breast ...

The European Commission has approved Daiichi Sankyo and AstraZeneca's Enhertu as the first targeted therapy for HER2-low breast cancer, unlocking a large population of patients who could be ...

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Tuesday said their cancer drug Enhertu received a priority review by the Food & Drug Administration in the US for some forms of breast ...